12 Jan 2007 - QSV Biologics, Ltd (QSV) and Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) announced the signing of a cGMP manufacturing agreement for TransMID(TM). QSV will be responsible for cGMP manufacture of further phase III clinical trial material and longer term commercial manufacture in their licensed cGMP manufacturing facility. TransMID(TM) is being developed for the specific treatment of progressive and recurrent non-resectable glioblastoma multiforme, a particularly dangerous type of brain tumor where the average life expectancy is less than six months upon diagnosis.
 |
www.bionity.com/news/e/60717 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/60717 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |